Clinical trials: Sexually Transmitted Infection
HIV Infections, Syphilis
Ending the HIV Epidemic Through Point-of-Care Technologies (EHPOC)
This study proposes to investigate the performance of existing and new technologies for HIV diagnosis, one of the key strategies for Ending the HIV Epidemic in the U.S.
- Trial name
- EHPOC (NCT04793750)
- Testing
- Cepheid GeneXpert HIV-1 Qual POC HIV VL test, DPP HIV-Syphilis test system, OraQuick
- Where
- 3 sites in United States
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
HIV Infections
A Stigma Reduction Intervention at Time of Entry Into Antenatal Care to Improve PMTCT Services in Tanzania
This study will pilot test a brief, scalable intervention called Maisha (Swahili for life), to address HIV stigma for women presenting to antenatal care in Tanzania and male partners who accompany them.
- Trial name
- Maisha (NCT03600142)
- Testing
- Mashia
- Where
- Tanzania
- Volunteers
- 1,539 people, healthy volunteers welcome
- Sponsor
- University of Utah
HPV InfectioN, HPV-Related Carcinoma
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years
A total of 18000 healthy women aged 18-45 years old were divided into three age groups: 18-26 years old, 27-35 years old, and 36-45 years old. The experimental group and the placebo group were randomly assigned in a ratio of 1:1.
- Trial name
- NCT06041061
- Testing
- Recombinant 14-Valent Human Papillomavirus Vaccine（Insect Cell）
- Where
- 5 sites in China
- Volunteers
- 18,000 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
AIDS
Safety and Immunogenicity Study of AIDS Vaccine (Combined Use of DNA Vaccine and Recombinant Vaccinia Virus Tiantan)
This trial studies the safety and immunogenicity of a HIV clade B'/C DNA vaccine followed by recombinant vaccinia virus rTV boost in HIV-uninfected healthy volunteers at low or high risk of HIV infection.
- Trial name
- NCT01705223
- Testing
- DNA vaccine, DNA vaccine prime with the addition of electroporation, rTV boost
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- National Center for AIDS/STD Control and Prevention, China CDC
Substance-Related Disorders, Sexually Transmitted Diseases
Adolescent Drug and HIV Prevention in South Africa
The purpose of this trial is to test the effectiveness of a classroom-based prevention program (HealthWise: Learning Life Skills for Young Adults) to reduce the risk of HIV/AIDS and STIs, as well as substance use, among…
- Trial name
- NCT00336180
- Testing
- HealthWise South Africa curriculum
- Where
- South Africa
- Volunteers
- 7,695 people, healthy volunteers welcome
- Sponsor
- Penn State University
HIV/AIDS
Acceptability, Feasibility and Preliminary Impact of OurPlan, an mHealth HIV Prevention Intervention for Male Couples
The study will evaluate the use and preliminary impact of an mHealth app for improving sexual health outcome measures among male couples by assessing whether exposure and use of the app results in improvements in participants and…
- Trial name
- OurPlan (NCT04836091)
- Testing
- Waitlist, Intervention
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Florida International University
Hiv, Syphilis
Validation of Self Testing Using the INSTI Multiplex HIV1/2 Syphilis Antibody Test
This study aims to validate the percent agreement of the INSTI Multiplex Human Immunodeficiency (HIV) 1/2 syphilis antibody (Ab) test (INSTI POCT) when used as a self-test by patients compared to conventional serologic testing.
- Trial name
- NCT06953024
- Testing
- INSTI HIV/syphilis Point of Care Self-Test Administration
- Where
- Canada
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Nova Scotia Health Authority
HIV Infections, Risk Reduction
Seroincidence Study Among Men Who Have Sex With Men and Transgender Women - The ImPrEP Seroincidence Study
PrEP (pre-exposure prophylaxis) is an effective prevention strategy in which HIV-negative individuals take antiretroviral drugs (tenofovir disoproxil fumarate and emtricitabine - TDF/FTC) to reduce HIV acquisition.
- Conditions
- HIV Infections, Risk Reduction, Risk Behavior, Risky Health Behavior
- Trial name
- Seroincidence (NCT05674682)
- Testing
- HIV testing
- Where
- 2 sites in Brazil
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Evandro Chagas National Institute of Infectious Disease
Osteoporosis
HIV UPBEAT: Understanding the Pathology of Bone Disease in HIV-infected Patients.
Despite the prevalence of osteopenia and osteoporosis in the HIV positive population, relatively little is known about the underlying pathology.
- Trial name
- UPBEAT (NCT01778361)
- Where
- Ireland
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- University College Dublin
HIV Infections
Pharmacokinetic Interactions Between Buprenorphine and Kaletra (Lopinavir/Ritonavir)
The main purpose of this protocol is to study the effect of an HIV medication, Kaletra (lopinavir/ritonavir), on buprenorphine in non-HIV infected people who have been receiving the same dose of buprenorphine for at least 3…
- Trial name
- NCT00571961
- Testing
- Kaletra (lopinavir/ritonavir), buprenorphine, Clinical evaluations/Blood draws
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Yale University
HIV, HIV Infections
Atazanavir/Ritonavir and Darunavir/Ritonavir PK Tail Study
The purpose of the study is to look at the levels of three HIV medications darunavir, ritonavir and atazanavir in the blood after the drug intake has been stopped in order to understand how long these drugs persist in blood for.
- Trial name
- NCT01073761
- Testing
- darunavir/ritonavir then atazanavir/ritonavir
- Where
- United Kingdom
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- St Stephens Aids Trust
Infection, Human Immunodeficiency Virus
A Study of the Relative Bioavailability of BMS-626529 Administered as BMS-663068 From 150mg Low-dose Extended-release Tablets Compared to 600mg Reference Extended-release Tablets in Healthy Subjects
An oral dose in healthy subjects to determine the relative bioavailabilty of BMS-626529 administered as BMS-663068
- Trial name
- NCT02859259
- Testing
- BMS-663068 (1 tablet at 600 mg), BMS-663068 (4 tablets at 150 mg each tablet)
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV/AIDS
Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel in HIV-1 Seronegative Adults
The purpose of the study is to evaluate the safety, acceptability, and PK/PD profile of maraviroc gel following rectal and vaginal administration. The study also includes oral exposure to maraviroc.
- Trial name
- NCT02346084
- Testing
- Maraviroc 300 mg tablet (PO) and Maraviroc 1% gel (PR and PV)
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- International Partnership for Microbicides, Inc.
Cervical Cancer
Web-Based Education Program and Educational Booklet Developed on Cervıcal Cancer
Cervical cancer is the fourth most common cancer type among women worldwide and ranks ninth in Turkey, making it the second most common gynecological cancer.
- Trial name
- NCT06705309
- Testing
- Web-Based Education
- Where
- Turkey (Türkiye)
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Istanbul University - Cerrahpasa
HIV Infections
A Peer-Driven Intervention to Increase PrEP Uptake Among Minority MSM
The objective of this study is to develop an effective peer-driven intervention (PDI) approach and assess its feasibility and efficacy on pre-exposure prophylaxis (PrEP) uptake among men who have sex with men.
- Trial name
- NCT05161663
- Testing
- Peer-driven intervention
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- The Miriam Hospital
HIV Infections
A Study of LIPO-5 and ALVAC-HIV (vCP1452) as Possible HIV Vaccines
This study will test the immune system response to and safety of two HIV vaccines alone and in combination: ALVAC-HIV (vCP1452) and LIPO-5. ALVAC-HIV (vCP1452) uses a canarypox virus with man-made parts of HIV attached to it.
- Trial name
- NCT00076063
- Testing
- ALVAC-HIV (vCP1452), LIPO-5
- Where
- 11 sites in United States
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV/AIDS
CareConekta: A Pilot Study of a Smartphone App in South Africa
Population mobility is frequent in South Africa and disrupts the continuity of HIV care. Postpartum, HIV-positive women are at elevated risk of dropping out of HIV care and are highly mobile.
- Trial name
- NCT03157908
- Testing
- CareConekta
- Where
- South Africa
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Cervical Cancer, Human Papilloma Virus
Research in Ethno-Medicine and Education (REMED)
The purpose of this study is to gain information about intravaginal practices, like intravaginal "twalet deba", among Haitian women living in South Florida.
- Conditions
- Cervical Cancer, Human Papilloma Virus, HPV, Human Papillomavirus Infection
- Trial name
- REMED (NCT05907187)
- Testing
- Cervical Cancer Prevention Education
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Miami
Papillomavirus Infections, Genital Diseases, Female
Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED)
This study was conducted in 2 parts. Part A was a randomized, double-blind, placebo-controlled, multicenter, sequential dose-escalating evaluation.
- Trial name
- NCT00365716
- Testing
- Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 20/40/40/20, Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40, Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80
- Volunteers
- 1,158 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
Workplace-based HIV Self-testing Among Men in Uganda (WISe-Men)
This study seeks to determine whether workplace delivery of HIV self-testing will lead to an increase in uptake of HIV testing and subsequent linkage to care or prevention services among men in Uganda.
- Trial name
- NCT04164433
- Testing
- Oral HIV Self-Test (OraQuick)
- Where
- 2 sites in Uganda
- Volunteers
- 548 people, healthy volunteers welcome
- Sponsor
- Makerere University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.